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1 INTRODUCTION 
1.1 Malaria burden 
Despite the tremendous progress in the fight against malaria over the past decade, the 
disease remains one of the most important infectious diseases. It was responsible for 
about 219 million cases and more than 435 000 deaths in 2017 worldwide (1).  
Due to the improved access to malaria interventions between 2001 and 2013, a large 
decline in the overall mortality rate of about 47% has been achieved. Particularly, in 
African children under five years of age, the mortality rate was reduced by 58%. During 
the same period, global malaria incidence was reduced by 30%.  
Based on this success, in the “Global technical strategy for malaria 2016 – 2030”, 
World Health Organization (WHO) has set goals of at least a 40% reduction in malaria 
mortality rates and case incidence between 2015 and 2020. However, over the last 
years, the decline in malaria burden has stalled (Figure 1). 
 
Figure 1. Malaria incidence (https://www.who.int/gho/malaria/epidemic/cases/en/) 
(with permission). 
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One possible explanation for the halted decline in malaria incidence is climate change 
(2). As discussed in the Roll Back Malaria’s Action and Investment to Defeat Malaria, 
2016 – 2030, change in temperature and rainfall may create new habitat for mosquitoes 
in several regions and could result in prolonging transmission season or increase the 
prevalence of vector, on the other side, drought could shorten transmission season and 
remove the vector’s habitat in some malaria-endemic areas. However, exposing these 
new regions and populations to malaria may result in higher incidence and death rates 
due to low acquired-immune level against malaria and lack of treatment.  
Another explanation involves the drug resistance of both vector and parasite. Since 
2000, a great reduction in malaria mortality and morbidity rate has been linked with an 
extension on access to the two core vector control interventions: insecticide-treated bed 
nets and indoor residual spraying, particularly in sub-Saharan Africa. However, these 
achievements have been threatened by the rise of resistance to insecticides in malaria 
vector population worldwide. If neglected, insecticide resistance could result in a 
substantial increase in malaria incidence and death rate.  
The emergence of drug and insecticide resistance is additionally constituted by some 
biological challenges including the high complexity of natural Plasmodium infection 
and diversity of malaria vectors. The former has been a major challenge for the 
development of new tools for malaria control and eradication e.g. vaccines and new 
antimalarial drugs. 
Gabon is located in Equatorial Africa where malaria is highly endemic. In rural Gabon, 
as reported in our recent study, there were about 74% of the screened individuals 
carrying Plasmodium parasites, and 66% of these carriers were infected with P. 
falciparum. In addition, the high prevalence of anti-malarial drug resistance especially 
chloroquine resistance (CQR) is often documented (3).  
1.2 Species and life cycle 
1.2.1 Human Plasmodium 
There are up to around 156 identified species of Plasmodium (4). Five of those are 
transmitted between humans and cause malaria: Plasmodium falciparum, P. vivax, P. 
malariae, P. ovale curtisi and P. ovale walikeri. P. falciparum is responsible for most 
cases and almost all deaths, especially in children under five years of age in Africa. P. 
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knowlesi is the sixth human malaria parasite. It causes a zoonotic disease that occurs 
only in Southeast Asia, where Macaca fascicularis and Macaca nemestrina, the main 
hosts, live.  
1.2.2 Life cycle 
 
Figure 2. Life cycle of Plasmodium spp. Source: CDC - DPDx/ Alexander J. da Silva, 
PhD; Melanie Moser (with permission). 
The unique and complex life cycle of the malaria parasite occurs within two hosts: 
mosquitoes and humans (Figure 2). Genetic recombination and meiosis happen after 
fertilization when the gametocytes are taken up during the blood meal of a female 
mosquito, developing into male and female gametes then mate and form a zygote. 
Plasmodium parasites are haploid except for the short diploid period (zygote) in the 
mosquito midgut. This unique trait allows the molecular approaches which target single-
copy nuclear genes for identifying the malaria parasite since each genotype will 
represent a variant (so-called “strain”). Recombination may generate new variants that 
help parasite evade host immunity. For every Plasmodium species, recombination 
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events occur only when a mosquito carries multiple parasite strains. As a consequence, 
recombination rates are directly associated with frequencies of multiple infections and 
transmission intensity. 
1.3 Natural P. falciparum infection 
1.3.1 Genetic complexity of P. falciparum infection 
1.3.1.1 Circulating parasite in peripheral blood (PB) 
In malaria-endemic regions, individuals are infected repeatedly, and often by multiple 
parasite strains. The number of circulating parasite strains may vary between different 
malaria episodes and within the same patient. Most of the reported multiplicity of 
infection (MOI) was often greater than one. Multiple-strain infection can be a result of 
multiple infectious bites or a single bite from a mosquito infected with multiple parasite 
variants. In addition, MOI of the same parasite population could be different due to the 
sensitivity of genotyping approaches (5). MOI was found to associate with seasonal 
transmission intensity, the manifestation of the disease in pregnant women (6) and the 
risk of treatment failure (7,8). There was evidence suggesting the existence of some 
parasite genotypes that relate to the severity of malaria (9,10). 
The multiplicity of malaria infection can complicate the identification of the individual 
strain. Minor strains can be suppressed by the major ones through resource competition 
(11), while the density of each parasite strain may change over the course of infection or 
even after treatment.  
A high diversity of parasite populations may intensify difficulties in the development of 
malaria vaccines. Often, the vaccine protective efficacy is stronger against homologous 
than heterologous controlled human malaria infections (CHMI) (12) or matched 
genotype than mismatched genotypes in natural infections (13). In addition, the concept 
of parasite “strain-specific efficacy” suggests those whole sporozoite vaccines – a new 
generation of vaccine candidates – may have better efficacy against natural infection if 
able to cover multiple parasite strains.  
1.3.1.2 Sequestering P. falciparum in human tissue 
Most knowledge on the in vivo behavior has been gathered by the investigation of 
circulating Plasmodium in the peripheral blood. In contrast, little is known about this 
parasite when they are in human tissues including the bone marrow parenchyma.  
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There is evidence that the human bone marrow (BM) is a preferable place for 
sequestration and gametocyte maturation of P. falciparum.  
Mature asexual P. falciparum stages (pigmented trophozoites and schizonts) and 
immature gametocytes are typically not found in peripheral blood (14). Smalley et al. in 
1981 have shown that in P. falciparum-infected children, the density of immature 
gametocytes on bone marrow smears was greater than that on peripheral blood smears 
(15), however, their distribution in each compartment of bone marrow (intra- or extra-
vascular) was not reported. 
Later, post-mortem histological evidence has revealed the presence of malaria parasites 
in extravascular compartments of different human tissues including spleen, heart, lung, 
gut, brain and bone marrow (16,17). It was shown that only a small proportion of 
mature gametocytes were in the extravascular compartment, the majority being in 
intravascular spaces (18). Asexual, immature parasites were detected in human 
autopsies in both intra- and extra-vascular compartments. Extravascular sequestration is 
suggested to be crucial for gametocytogenesis and transmission of Plasmodium to the 
mosquito (19).  
In addition, analysis of sequestering parasite by molecular technologies like polymerase 
chain reaction (PCR) has rarely been done (20), especially for bone marrow samples; 
although such investigations may help in understanding the pathogenesis of the severe 
forms of malaria, particularly anemia and severe anemia. 
1.3.2 Diverse disease manifestation 
1.3.2.1 Asymptomatic parasitemia 
Asymptomatic parasitemia is defined as the presence of Plasmodium parasites (asexual 
forms) in circulation of the infected individual without any associated symptoms (21). 
In highly endemic areas, asymptomatic parasitemia occur mostly in adults, consist an 
important proportion of the overall prevalence of infection (3) and is considered as the 
most important infectious reservoir.  
1.3.2.2 Uncomplicated malaria 
In contrast with asymptomatic parasitemia, in uncomplicated malaria, the presence of 
parasitemia in circulation of infected individual is accompanied by malaria-associated 
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symptoms without signs of severity or of any vital organ dysfunction. This is the most 
common manifestation of malaria in endemic region and is often observed in children. 
1.3.2.3 Severe malaria 
Most malaria attributable deaths and severe disease are caused by P. falciparum. Other 
non-falciparum species were also found to cause severe malaria and the co-infection of 
different Plasmodium species could lead to more severe hematological impairment (22). 
1.3.2.3.1 Symptoms defining severe falciparum malaria 
Severe falciparum malaria is defined when a patient is infected with P. falciparum with 
the presence of one of the signs of severity or vital organ dysfunction. Severe 
falciparum occurs mostly in children under 5 years of age and often in some following 
forms: cerebral malaria (CM), metabolic acidosis, severe anemia, hypoglycemia, 
pulmonary and renal dysfunction (23). 
1.3.2.3.2 Severe malarial anemia 
Anemia is defined as a hemoglobin (Hb) concentration of lower than 10.9 g/dL (1). 
Using WHO’s classification guideline, between 2015 and 2017, among children aged 
under 5 years, the overall prevalence of mild, moderate, severe and any anemia was 25, 
33, 3 and 61%, respectively compared to 21, 50, 8 and 79% in group of children who 
tested positive for malaria by RDT. In tropical regions, not only by malaria, anemia is 
often caused by other concomitant reasons including other infections (sepsis, intestinal 
helminthic infection, schistosomiasis), nutritional deficiencies, hemoglobinopathies 
(thalassemia and sickle cell disease) or other red blood cell abnormalities like glucose 6 
phosphate dehydrogenase (G6PD) deficiency (24,25). Anemic children are at a higher 
risk of developing severe disease including severe malaria. 
In other forms of severe malaria e.g. cerebral malaria (CM), metabolic acidosis, renal 
failure, accumulation and sequestration of parasites in the microvasculature which 
results in microvascular obstruction and tissue hypoxia is considered the main 
pathophysiological mechanism. However, the role of malaria parasite in the 
pathogenesis of anemia is controversial. 
Research efforts in understanding the pathogenesis of malarial anemia have suggested 
the multifactorial relation between SMA and increased red blood cell (RBC) destruction 
as well as impaired RBC production. The mechanisms of removing RBCs from the 
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circulation system involves the destruction of RBCs, by a filtration mechanism in the 
spleen, and phagocytosis. Apparently, parasite-induced destruction of parasitized RBC 
contributes to the reduction in RBC count, however, parasitemia alone is often not 
correlated with anemia severity, while the lysis of un-parasitized RBC was 
demonstrated to be the main contributor to rapid hematological impairment (26). 
In peripheral blood, the association between severity of malaria (especially SMA) and 
structure as well as the diversity of the P. falciparum population has been described 
repeatedly. However, little is known about their local role, e.g. in bone marrow, and it is 
not clear whether the population structure of P. falciparum in bone marrow is associated 
with the disease pathogenesis. 
1.4 Diagnosis  
1.4.1 Malaria diagnosis  
The outcome of malaria – especially P. falciparum malaria – relies crucially on a timely 
and reliable diagnosis that determines treatment and management. To achieve that, 
microscopy of thick blood smears and/or malaria rapid diagnostic test (RDT) have been 
recommended (21,27). Although TBSs are still considered the standard diagnostic tool, 
malaria RDTs have been used routinely in many field sites as well as in clinical 
practice, particularly where microscopy is not available (27–29). In Sub-Saharan Africa, 
RDTs have been increasingly used to test for malaria, from 40% of the tests were 
performed using RDTs in 2010 to an estimated 75% in 2017 (1). 
The expansion in the use of RDT has resulted in an increase in sales of RDTs in Africa 
from 240 million in 2015 to 276 million in 2017 (1,29). The availability and common 
use are making RDTs more attractive to research that aims to explore other utilities of 
this tool e.g. a source of DNA for PCR and other molecular assays.  
1.4.2 Sample for diagnosis and studying malaria parasite 
In addition to the selection of the adequate method, the rate of success in making 
diagnosis and genotyping malaria parasites in therapeutic studies might be improved by 
standardizing blood sampling and storage conditions.  
Sample collection in field trials is often done by field workers, therefore, the material 
should be available in remote regions, collection procedure should be technically easy 
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and shipment should be at ambient condition. It is also of crucial importance to prevent 
samples from contamination and degradation of molecular material. 
The molecular material for PCR is usually recovered from venous blood, blood spotted 
on filter paper (FP) (30) or thick blood smears (TBS) (27,31). Venous whole blood 
sampling is able to serve multiple tasks, including RNA and DNA extraction. It is 
proven that whole blood samples produce higher quality and quantity of DNA and are 
easy to handle for DNA extraction. However, venous blood sampling is invasive, 
requires professional training, special storage and shipping conditions and may result in 
noticeably lower diagnostic sensitivity compared to capillary blood (27,32). In addition, 
collection tubes must be treated with anticoagulants which can inhibit PCR reactions.  
TBS is not commonly used as a source of DNA for molecular assays since the quality of 
DNA recovered from TBSs is often lower compared to that from filter paper and fresh 
blood (33). 
Capillary blood samples can be collected by finger prick and are used for the 
preparation of TBSs, filter paper and RDTs. Capillary blood sampling is often the 
method of choice for withdrawing blood from children and when only a small amount 
of sample is required. This approach is simple and considerably less invasive. 
Since 1995, whole blood spots on filter paper has been most commonly used as a source 
of DNA for PCR in clinical trials (34). Filter paper can be shipped and stored at room 
temperature and some materials facilitate the extraction process. The quality of 
extracted DNA changes according to the filter paper types and extraction procedures.  
Similar performance was observed between some filter papers commonly used in 
Plasmodium detection by PCR (35,36).  
PCR has been successfully performed using DNA recovered from RDTs (37–40) and 
the amplification success rate was comparable to that of filter paper (41). However, 
validation of the use of RDTs has been limited to some types of molecular approaches, 
mostly aimed at detecting parasite and genotyping some common drug-related mutant 
genes. The use of RDTs as a source of DNA for assessing and monitoring the diversity 
of parasite population (e.g. msp genotyping) is nevertheless uncommon (27). 
Therefore, validation of the performance of RDTs as a source of DNA for different 
molecular assays and optimization of the extraction method for the ease of use is of 
importance (27). 
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1.5 Current molecular methods for genotyping malaria parasite  
1.5.1 Genetic markers  
1.5.1.1 Merozoite surface proteins 
Research efforts in the 80s and 90s have suggested that the merozoite surface antigens 
(MSAs) p190 (later known as MSA1), 513 (MSA2) together with the glutamate-rich 
protein (GLURP) are polymorphic. Analysis of DNA sequences of laboratory strains 
and field samples has demonstrated that gene coding MSA1 and MSA2 can be divided 
into blocks that are variable or conserve (42). Due to the polymorphism in length,  the 
variable regions of genes coding MSA1 (block 2, on chromosome 9), MSA2 (block 3, 
on chromosome 2), and GLURP (R2 region, on chromosome 10) were considered the 
most useful markers for PCRs aim at genotyping P. falciparum (43) as later 
recommended by WHO (44). This method was considered a standard in many clinical 
trials conducted between 1995 and 2005 (34). While the assessment of MOI is generally 
based on the genotyping result of one of the three markers, the distinction of parasite 
strains may rely on two or even all three markers. In recommended protocols (44), msp2 
was considered the primary marker for genotyping P. falciparum followed by glurp; 
msp1 was only used when these two markers were not able to differentiate parasite 
strains. The reason for this less common use of msp1 as the primary marker could be 
that the identified polymorphic locus was short (often shorter than 500 bp) and the size 
change is often too small to be analyzed by gel electrophoresis. Later, by using capillary 
electrophoresis (CE), msp1 and msp2 genes were demonstrated to have the same high 
polymorphism and could be alternatively used as the primary marker for PCR-based 
genotyping assays and the use of glurp could be considered if the distinction is failed 
with msp1 and msp2 (45).  
1.5.1.2 Single nucleotide polymorphisms (SNPs) 
In humans, single nucleotide polymorphism (SNP) barcoding has been proposed as an 
alternative to short tandem repeats for kinship testing.  
In malaria research, the first molecular SNP “barcode” for genotyping P. falciparum has 
been introduced by Daniels et al in 2008. It encompasses 24 bi-allelic chromosomal 
SNPs distributed across 14 chromosomes of the P. falciparum genome and was used as 
a fingerprint of the parasite genome (46). This methodology in combination with high-
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resolution melt analysis requires a small amount of sample, is comparatively 
inexpensive and was capable of identifying polyclonal infections (47).  
The abovementioned nuclear SNP barcode has some limitations including the lack of 
geographical specificity. In 2014, another molecular barcode has been explored 
comprising SNPs distributed in extra-nuclear genomes of the mitochondria and 
apicoplast organelles of P. falciparum (48). The barcode was chosen from analyzing the 
reference genome of P. falciparum strain 3D7 together with raw sequences data from 
711 P. falciparum isolates collected from five geographic regions. A further analysis 
has resulted in a minimal barcode that is comprised of five mitochondrial and 18 
apicoplast SNPs and showed high predictive accuracy in tracing the geographic origin 
of the parasite. Later, another barcode consisting of 42 nuclear SNPs was explored for 
genotyping P. vivax (49).  
1.5.1.3 Microsatellite 
Hundreds of microsatellites or simple sequence repeats have been described and used 
for studying population structure in malaria research. Selected microsatellites that are 
not under immune selection are often used. Since their individual size is the multiple of 
the known repeat unit, genotyping results can be better compared across different 
samples and laboratories. The size of the microsatellites is often measured by capillary 
electrophoresis on sequencers, and their diversity in length could serve to estimate 
population structure.  
Microsatellite typing in malaria research often involves PCR amplification of several 
microsatellites. With the limited number of variants at each locus, the discriminatory 
power of this genotyping approach is low if only one or two microsatellites are used; 
measuring a high number of microsatellites, on the other hand, complicates the 
genotyping process. 
1.5.1.4 Other length polymorphic markers 
Additional markers, such as polymorphisms in csp, ama and trap genes have been used 
in malaria research (50–52). However, their use in general strain distinction analyses is 
uncommon due to low polymorphism in length. 
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1.5.2 Technical approaches for genotyping malaria parasite 
1.5.2.1 Conventional-PCR-based methods 
Due to their ease of use, low cost, modest hardware requirements and, genotyping 
approaches based on conventional PCR are still commonly used in malaria-endemic 
areas. The target genes of these genotyping approaches shall be polymorphic to 
maximize the discriminatory power. Often length polymorphisms are chosen and the 
size of the last PCR product is analyzed directly or after being fragmented by a 
restriction enzyme on either agarose gel or capillary electrophoresis system. 
1.5.2.1.1 Size analysis by Agarose gel electrophoresis 
Following the amplification step by PCR, agarose gel electrophoresis is the most 
popular method for the size analysis of the PCR products, mostly because of its low cost 
(27). However, this conventional approach is limited by the low resolution and may not 
provide accurate discrimination of alleles especially in endemic regions where high 
MOI can lead to i) missed detection of minor alleles due to low parasite density, and/or 
ii) misinterpretation since small differences in the length between alleles may be 
misclassified by gel electrophoresis.  
1.5.2.1.2 Size analysis by capillary electrophoresis 
a. On a sequencer 
An alternative technique for fragment size analysis is CE on DNA sequencers. When 
used for genotyping a length polymorphic marker, the targeted gene will be amplified 
by PCR using one pair of fluorescence dye-labeled oligonucleotide primers. Final PCR 
products (amplicons) then undergo the fragment separation process by CE and the 
fluorescence signal will be detected by a laser. The fragment size (in base pair) is 
estimated based on their migration time in relation to the standard calibrator. When used 
for allelic typing (e.g. microsatellites), different fragments can be detected 
simultaneously by the use of primers labeled with distinct dyes. CE has provided a more 
accurate estimation of allele size than gel electrophoresis (53). This can improve the 
accuracy of discrimination between recrudescence and new infection and thereby refine 
the study of drug efficacy in clinical trials especially when conducted in high endemic 
areas (54). However, relying upon sequencer and fluorescent-labelled primers is costly, 
demanding and difficult to be used in field sites. 
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b. The QIAxcel Advanced System (Qiagen) 
The QIAxcel Advanced System (Qiagen) is one of the commercialized CE systems, 
manufactured to replace the conventional gel-based sizing analysis of DNA, RNA, and 
proteins. It consists of 12 independent capillaries. The system is designed for the sizing 
analysis of a batch of 96 samples on a plate each run with a resolution of 3–5 bp. The 
PCR product could be analyzed directly in an automated system to avoid hands-in 
procedures and cross-contamination. In addition, the preparation procedure could be 
simplified followed by a decreased cost due to the normal PCR condition which does 
not require florescence-dye labeled primers. In an analysis, the size of the target product 
is estimated based on their migration time in relation to that of a size marker and an 
alignment marker (which can be pre-calibrated) using built-in software.  
1.5.2.2 SNP barcoding assays 
To the time of this thesis, a set of primers and probes for genotyping 24 polymorphic 
SNPs of P. falciparum (see 1.5.2.1) using allelic discrimination (AD) assay is 
commercially available. This multiplexed, end-point assay has two primer/probe pairs in 
each reaction, that allows for the detection of the two possible variants at each SNP. In 
an AD assay, a unique pair of fluorescent dyes (FAM and HEX/VIC) was used to label 
24 pairs of TaqMan
 
MGB probes that target 24 SNP positions. One fluorescent dye-
labelled probe is a perfect match to one allele and the other is a perfect match for the 
other allele. During the PCR, the fluorescence dye will emit after being cleaved from 
the matched probe by the polymerase, the emission will be detected and measured 
(Figure 3). 
 
Figure 3. Illustration of AD assay. Source: Applied Biosystem's Allelic Discrimination 
Assay Getting Started Guide for the 7900HT System (55)(with permission). 
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The results are visualized on a scatter plot based on the intensity of the fluorescence 
signals of the two dyes which were measured at the plateau phase of the amplification. 
The barcode has been used in some studies and the robustness was compared with 
conventional (msp gene-based) methods (47,56). The overall performance of the entire 
barcode is not superior to the conventional msp genotyping approach, mostly due to the 
low polymorphism of some SNPs in the studied regions. Minimal but regionally 
specific barcode with a smaller number of SNPs has been shown to potentially simplify 
the genotyping procedure (56). Therefore, validation and optimization of a specific 
barcode for the ease of use in the study area are of particular interest. 
1.5.2.3 Next generation sequencing 
Next-generation sequencing (NGS) has been used for the analysis of the diversity of 
malaria infection in some trials (57). NGS-based genotyping is able to detect and 
analyze minor alleles hence often results in higher MOI of P. falciparum compared to 
the conventional method (5). Despite the excellent resolution, NGS is not recommended 
for use in the field settings due to some limitations: mostly, cost and complicated 
preparation and analysis procedures. 
1.5.2.4 Other genotyping approaches 
Some other alternative approaches have been used for genotyping Plasmodium in order 
to distinguish recrudescence from new infection: Southern blotting of paired PCR 
products (58), single-strand conformation polymorphism (SSCP) (59). However, these 
methods are not widely used and less standardized (44).  
1.6 The implementation of parasite genotyping  
1.6.1 Determination of drug efficacy in therapeutic trials 
In drug trials which aim to assess the efficacy of antimalarial treatments for 
uncomplicated malaria, the estimation of efficacy relies crucially on the level of 
recurrent parasitemia that occurs as result of a recrudescence or a new infection. “New 
infection” and “recrudescence” are commonly referred to as a difference of parasite 
strains detected from the pre-treatment sample and recurrent sample. Briefly, a ‘new 
infection’ is a recurrence of parasitemia after clearance (by treatment), of which, all 
detected alleles are different from those in the admission sample, on the other side, in 
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‘recrudescence’, at least one common allele at each locus is detected from both samples. 
“Recrudescence” is often considered treatment failure due to drug resistance.  
However, it is not possible to clinically or morphologically (e.g. by microscopy) 
distinguish a recrudescence from a new infection. To make this distinction, molecular 
genotyping techniques are the method of choice, in order to determine whether a sample 
from admission and recurrent infections carry identical or different parasite strains. 
Misclassification of recurrent infections (“recrudescence” or “new infection”) could 
possibly lead to imprecise estimation of drug efficacy and delayed curative treatment. 
Therefore, the World Health Organization has recommended the use of molecular 
genotyping techniques for all antimalarial drug efficacy trials in highly endemic 
settings. 
1.6.2 Assessment of complexity of infection 
Several parasite and host factors have been described to associate with malaria 
virulence, including parasite species, level of immunity and efficacy of treatment. 
Within-host diversity of the infecting parasite population and the polymorphism pattern 
of some genes have been described to associate with the clinical outcome of malaria 
(9,10,60). In addition, MOI was proposed as a secondary measurement to assess the 
outcome of intervention trials (61). 
Besides the importance of distinguishing parasite strains, diversity of parasite 
population – often represented by MOI, has also been commonly studied. Assessment of 
MOI relies upon the sensitivity of the methodology used, may vary between different 
laboratory settings and is difficult in complex infection, especially in infection with low 
overall parasite density, or infection where the density of a minor strain is low. In 
addition, compilation and/or comparison of genotyping outcomes between sites or 
within a site at different time points is often compromised by the use of non-validated 
methods. 
Therefore, it is of importance to establish, validate and standardize the genotyping 
approaches that are reproducible, cost-effective, field deployable, simple to perform and 
able to provide genotyping results in order to detect parasite strains with low density 
and help to assess MOI with high accuracy. 
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1.6.3 Documentation of drug resistance 
Antimalarial drug resistance has been described mostly for P. falciparum and P. vivax. 
P. falciparum has been reported to develop resistance to nearly all current antimalarials 
drugs especially chloroquine. 
Resistance to chloroquine (CQ) of Plasmodium was first documented in the Greater 
Mekong region after World War II and quickly spread to Africa. The spread of CQ 
resistance was followed by a deplorable treatment failure rate worldwide and has 
contributed to a frightening increase in malaria mortality in the second half of the 20th 
century. At their intra-erythrocytic stage, P. falciparum parasites take up hemoglobin 
and host cytoplasm to grow and replicate. Hemoglobin digestion happens in an acidic 
digestive vacuole and releases toxic hematin that – if accumulated – may cause parasite 
death. CQ is proposed to kill the parasite by interfering with the excretion of hematin 
which results in the accumulation of this toxic product inside the parasite (62). 
Examination of CQ-sensitive and resistant clones have localized the CQ resistance 
determinant to the P. falciparum chloroquine resistance transporter (Pfcrt) gene on 
chromosome 7. Four out of 10 described point mutations happen from locus 72 to 76 of 
Pfcrt gene, namely C72S, M74I, N75E, K76T are common in P. falciparum populations 
in Africa (63). Some point mutations are often found to happen together and the most 
frequently observed response haplotypes in Africa are CVMNK (the wild type or CQ 
sensitive), SVIET (CQR) and SVMNT (CQR). The haplotype SVMNT and other point 
mutations are very rarely observed in this region (3). 
Artemisinin-based combination therapies (ACTs) has become the replacement for CQ 
as the first-line treatment for uncomplicated malaria. Although ACTs remain the most 
effective treatment, resistance against artemisinin derivatives and partner drugs have 
been documented. Artemisinin resistance is associate with delayed parasite clearance 
and usually does not lead to complete treatment failure. Resistance to the partner drug is 
more frequent and may require a change in regimen. However, in most of the cases, 
patients can still be cured with ACTs (64). 
The mechanism that maintains the high prevalence of CQ-resistant haplotypes and other 
drugs is not well understood. Therefore, regularly monitoring drug resistance is of 
importance (65). 
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2 OBJECTIVE 
Against this background, my thesis was aimed to assess the performance on a large 
scale of archived RDTs as a source of DNA for molecular assays that aim at detection, 
estimation of parasite diversity, and characterization of chloroquine resistance of P. 
falciparum in asymptomatic parasitemia and uncomplicated malaria. The current 
prevalence of CQ-resistant haplotypes in Gabon was correspondingly reported.  
In order to enhance the resolution and robustness of parasite genotyping, this thesis was 
focused on establishing molecular tools including i) msp1-gene-targeted PCRs followed 
by the sizing analysis on an automated and affordable CE system, and ii) a minimal 
SNP barcode for discrimination of parasite strains for the use in drug trials in Gabon. 
As an exploratory objective, in this thesis, I utilized the msp1-gene-targeted genotyping 
method to assess the diversity of P. falciparum parasite populations in peripheral blood 
and bone marrow of anemic malaria patients and the association between parasite 
diversity and severity of malarial anemia. 
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3 METHODS 
3.1 Declaration of ethical approval 
The study entitled “Characterization of population genetic diversity and molecular 
genotypes of drug-resistant Plasmodium falciparum using samples from routine Rapid 
diagnostic tests in Gabon” was approved by the scientific review committee and the 
Institutional Ethics Committee (CEI) of CERMEL. 
The archived RDTs were mainly collected from a clinical trial (NCT03201770) named 
“Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The 
Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based 
Combination Therapy Pyramax®” which was approved by the Institutional Ethics 
Committee of CERMEL and the National Ethics Committee for research of Gabon – 
Comité National d'Ethique pour la Recherche (CNER). 
The ethics committees of the International Foundation for the Albert Schweitzer 
Hospital in Lambaréné and the ethics committees of the University of Münster and the 
University of Tübingen, Germany have approved the study entitled “A longitudinal 
study comparing age-matched triplets to investigate the etiology of severe anemia in 
children with Plasmodium falciparum malaria in Lambaréné, Gabon”. Bone marrow 
and peripheral blood samples collected for the study were used for this thesis. 
3.2 Study sites and sample collection 
3.2.1 Study site 
Clinical samples were collected in Lambaréné – Gabon. In vitro cultured P. falciparum 
parasites were reared at the Institute of Tropical Medicine – University of Tübingen – 
Germany. DNA extraction for RDT samples and filter paper, Pfcrt genotyping PCR was 
done in Lambaréné – Gabon. All other laboratory procedures were performed at the 
Institute for Tropical Medicine in Tübingen. An aliquot of the extracted DNA from 
RDTs was transported to Tübingen, another half was kept at -200C at CERMEL. 
3.2.2 Standard calibrator 
The preparation of the standard calibrator was described in detail else where (27). In 
brief, a field sample (with TBS parasitemia of P. falciparum of 6 840 000 p/mL) 
obtained from a malaria patient was ten-fold serially diluted with malaria-free group O+ 
18 
 
blood (lowest parasitemia 68 p/ml). Five µl of each dilution (6 dilutions) was spotted on 
new RDTs (SD BIOLINE Malaria Ag P.f/Pan) and 10µl was spotted on each circle of 
filter papers (Whatman ™ 903 Protein Saver Card). All 6 RDTs and filter papers (6 
circles) were kept at ambient temperature overnight before DNA extraction (27). 
3.2.3 Archived RDT collection  
As a part of the screening process of an ongoing drug trial (NCT03201770) and routine 
clinical activities, RDTs were collected and stored from June 2017 to July 2018. The 
full panel of inclusion and exclusion criteria could be retrieved from the trial registry 
NCT03201770 (27). 
Three different types of RDTs – all WHO prequalified – were used: VIKIA® Malaria 
Ag Pf/Pan (IMAccess, Lyon, France), Paracheck Pf® (Orchid Biomedical Systems, 
Goa, India) and SD BIOLINE Malaria Ag P.f/Pan (Standard Diagnostics Inc, Hagal-
Dong, Korea). The general lower limit of detection of these three types of RDT is ≤200 
parasites/µl, according to manufacturers’ specifications. Archived positive RDT 
cassettes were allowed to dry then stored at ambient temperature in a sealed pouch, until 
further use (27).  
During the study time from June 2017 to July 2018, a total of 1008 used RDT cassettes 
have been collected, RDTs that had both demographic data and positive readable test 
lines (with P. falciparum) were used for further investigations (27). 
3.2.4 Sample preparation for barcoding assay 
Samples for validation of the SNP barcoding assays were taken from the P. falciparum 
in vitro culture. Briefly, six P. falciparum laboratory strains were cultured: 3D7, HB3, 
Dd2, 7G8, D10, and W2. Parasites were gathered at the ring stage (parasitemia of the 
culture was approximately 3.5% and consists of >95% ring form, quantified by 
microscopy and fluorescence-activated cell sorting – FACS) and used for the assays. 
For the lower limit of detection assays (LLODs), two P. falciparum strains 3D7 and 
Dd2 were used. The templates’ DNA concentrations were measured using the Nanodrop 
spectrophotometer, each sample was measured five times and the mean concentration 
was used to generate the sample’s serial dilution. A serial dilution of a DNA mix (of 
3D7 and Dd2) was prepared (material extracted from culture is devoid from human 
DNA) as shown in Table 13. 
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To assess the utility of the SNP barcoding assays in distinguishing recrudescence and 
new infections: seven pairs of samples were taken from a drug efficacy trial conducted 
in Lambaréné – Gabon (NCT02198807), each pair had one sample collected on 
admission (visit Day 0, before treatment) and the other was collected at day of 
recurrence (Day X). 
3.2.5 Bone marrow and blood collection – SMA study 
A total of 91 children were recruited into this study after all inclusion and exclusion 
criteria had been full-filled, briefly:  
Inclusion criteria: 
• Written or witnessed informed consent by parent/guardian  
• Infection with P. falciparum. 
• Parasitemia > 1,000 parasites/µL 
• Age 1 year to 6 years 
• Plasma iron >10µmol/L 
• Leukocytes <12,000/µL 
- MCV ≥ 70fL in children aged 1-2 years 
- MCV ≥ 73fL in children aged 2-4 years 
- MCV ≥ 75fL in children aged 5-6 years 
• MCH between 28 and 34pg 
• HbAA or HbAS 
• Residency within 100km 
Additional entry criteria for group SMA: 
• Severe normochromic normocytic anemia with Hb ≤ 5g/dL and Hct ≤ 15% 
Additional entry criteria for group MMA: 
• Age matched (± 6 months) to a child from SMA group 
• Hb > 5g/dL and < 10g/dL 
• Thrombocytes > 30,000/µL 
• Lactate < 3mM 
• Blood glucose > 50mg/dL 
• No signs of complicated malaria 
Additional entry criteria for group MMW: 
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• Age matched (± 6 months) to a child from SMA group 
• Hb ≥ 10g/dL 
• Thrombocytes > 50,000/µµL 
• Lactate < 3mM 
• Blood glucose > 50mg/dL 
• Hemozoin-containing neutrophils < 2% 
• Parasitemia of between 1,000 and 100,000 parasites/µL, no schizonts 
• No hospitalization due to malaria in patient history 
• No malaria treatment as measured by Wilson&Edeson test (for chloroquine and 
quinine) and Lignin-Test (for sulfonamides) 
Exclusion Criteria: 
• Sickle cell anemia  
• Malnutrition (body size and body mass index below 80th percentile) 
• Blood transfusion within the past month 
• Signs of complicated malaria (other than anemia or hyperparasitemia): cerebral 
malaria, renal or pulmonary dysfunction. 
• Known filarial (Loa loa, Mansonella perstans), bacterial or viral infection (HIV, 
HBV, HCV, Parvovirus B19) 
• Other severe diseases, including malignant disease, renal, hepatic or pulmonary 
dysfunction not due to malaria 
• External or internal bleeding. 
Patients were enrolled and classified into three groups based on the peripheral 
Hemoglobin (Hb) concentrations at the admission visits. All patients were hospitalized 
and were treated with quinine and clindamycin (standard regimen at the time at the 
Albert Schweitzer Hospital) (66). 
Blood transfusion and other supportive treatment were upon study clinician’s judgment. 
The active follow-up period was two months (treatment period day 0 to day 4, control 
visits on day 14, day 28 and day 56) and was prolonged for 2 more months (from the 
last infection) in case of recurrent parasitemia.  
Blood sampling: From each patient, 5 ml of heparinized blood and 1 ml of EDTA 
treated blood was obtained directly before antimalarial treatment and blood transfusion. 
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500 µL of blood was stored at -80°C in glycerolyte (1.3 mL of glycerolyte was added to 
1000 µL blood). 
Bone marrow aspirations used for this work were taken on admission (Day 0) and on 
day 56. Bone marrow was aspired from the posterior iliac spine either under local 
anesthesia or under midazolam/pethidine anesthesia. Informed consent for the procedure 
was taken separately and study participation was independent of the willingness to 
undergo bone marrow puncture. 2mL of bone marrow was aspired (1mL to EDTA-
coated tube, 1mL to the heparinized tube) and frozen at -80oC together with glycerolyte 
(500 µL blood + 700 µL glycerolyte). 
Positive controls (P. falciparum strain 3D7 for 18S RT-PCR, strain 3D7 for msp1/K1, 
strain Dd2 for msp1/MAD20 and strain 7G8 for msp1/RO33) were prepared using 
cultured parasite. We used malaria parasite-free blood as negative controls for 
molecular assays. 
3.3 Nucleic acids extraction 
3.3.1 RDT and filter paper preparation 
3.3.1.1 Archived RDTs 
RDT cassettes were opened individually using scissors and forceps. After each sample, 
scissors and forceps were sterilized in alcohol 100% and DNA AWAY™ solution 
(Molecular BioProducts, San Diego, USA.) (27) then allowed to dry at room 
temperature before working with other RDTs. 
The test strip (nitrocellulose part) was taken out from the case and any plastic cover on 
the strip was stripped off (27). The part of the test strip (see Figure 4) which contains 
DNA was dissected and used for DNA extraction (67). DNA was eluted in 50 µl.  
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3.3.1.2 Filter paper 
The DNA extraction was done using a half of each circle (containing approximately 5µl 
of the sample) of filter paper (27). Elution volume was 50 µl. 
3.3.2 Peripheral blood and bone marrow samples  
For both peripheral blood and bone marrow samples, DNA extraction was done using 
the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instruction for blood (27). Fifty µL of PBS 1X was added to each 
sample before adding proteinase K and starting extraction. The elution volume was 100 
µl.  
3.3.3 Nucleic acids extraction protocol 
Nucleic acid extraction from cultured parasites, RDTs, and dried blood spots was 
performed using QIAamp DNA Blood Mini Kit (Cat No: 51106) (27) following 
manufacturer’s instruction.  
The common extraction procedure was as follow: 
- Add protease from the QIAamp DNA Blood Mini Kit (the amount depends on 
the type of sample, mentioned below) 
- Transfer sample (amount depends on the type of sample) to a 2 mL Eppendorf 
tube 
- Add lysis buffer AL (amount depends on the type of sample) and mix by 
vortexing for 15 seconds 
Figure 4. Illustration of RDT preparation for DNA extraction. 
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- Spin tubes shortly to remove drops from the inside of the cap 
- Incubate at 56°C for 10 minutes while shaking 
- Spin tubes shortly to remove drops from inside of the cap 
- Add 100% Ethanol (similar to the volume of buffer AL) and mix by vortexing 
for 15 seconds 
- Spin tubes shortly to remove drops from inside of the cap 
- Load lysate to a QIAamp Mini spin column without wetting the rim and 
centrifuge at 6000x g (8000 rpm) for 1 min. (Repeat this step until all lysate are 
applied to column) 
- Place the column in a clean 2 mL collection tube 
- Add 500 µL wash buffer AW1, without wetting the rim and centrifuge at 
6000xg (8000 rpm) for 1 minute 
- Place the column in a clean 2 ml collection tube 
- Add 500µL wash buffer AW2, without wetting the rim and centrifuge at full 
speed (17000xg) for 3 mins. 
- Place the spin column in a clean collection tube and centrifuge at full speed 
(17000xg) for 1 min to remove all wash buffer residues from the column. 
- Place the spin column in a sterile, DNase/RNase-free certified 1.5 mL Tube 
- Add 100µL (50µL for RDT and filter paper) pre-warm DNAase-free water 
directly to the filter of the spin column. 
- Incubate for 3-5 min at room temperature and centrifuge for 2 min at 6000xg 
(8000rpm) to elute total NAs. 
Table 1. Volume of samples and reagents used for extraction according to the type of 
sample. 
 
Sample volume (µL) Protease (µL) Buffer Al (µL) 
Parasite culture 200 20 200 
RDT 5 20 200 
Filter paper 5 20 200 
Blood in glycerolyte 150 (+ 50 µL of 1x PBS) 20 200 
Bone marrow in glycerolyte 150 (+ 50 µL of 1x PBS) 20 200 
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3.4 Real-time PCR for quantification of malaria parasite (18S RT-PCR) 
Malaria parasite detection and quantification were done using a Taqman probe-based 
Pan-Plasmodium Real-time PCR that targets a highly conserved region of 18S rRNA as 
described elsewhere (27,68) with a modification: reverse transcriptase was not used. 
Primers and probes sequences used for the assay are described in Table 4.  
Reaction mixes was made using TaqMan™ RNA-to-CT™ 1-Step Kit (Thermo Fisher 
Scientific, Foster City, CA, USA) following the manufacturer’s instructions for non-RT 
PCR.  
Table 2. Master mix preparation for 18S Pan-Plasmodium quantitative real-time 
PCR. 
Reagent component Volume 
Final 
concentration 
TaqMan® RT-PCR Mix (2X) 5 µl 1x 
PLU3 TaqMan Probe (10µM) 0.15 µl 150nM 
PLU3 Forward Primer (10µM)   0.4 µl 400nM 
PLU3 Reverse Primer (10µM) 0.4 µl 400nM 
Total Nucleic acids 2.5 µl  
Nuclease-free H₂O 1.55 µl  
Final volume per reaction  10 µl  
 
After the preparation, on a robotic pipetting system (QIAgility, Qiagen, Germany, Cat 
No./ID: 9001532), master mix was loaded into each well of a 384-well PCR plate 
together with DNA extracted from samples (in triplicate), one positive control (P. 
falciparum NF54) and one non-template control (in duplicate for both negative and 
positive controls). PCR was done on a LightCycler 480 Instrument II (Roche, Basel, 
Switzerland) with the following thermal conditions: 
25 
 
Quantification analysis was done with LightCycler® 480 SW v1.5.1 software. 
Successful amplification was defined as a Ct-value of lower than 40. 
3.5 Nested PCR for identification of Pfcrt mutations 
Nested PCR was used to genotype codons 72 – 76 of the Pfcrt gene, primers, and probes 
sequences are given in Table 4.  
To improve the sensitivity, Pfcrt gene was pre-amplified by conventional PCR as 
follows (27): 20µl of total reaction volume was made by adding 2.5µl of the template to 
17.5µl of a master mix containing: 1x PCR buffer, 0.4µM of each primer, 0.25 mM 
dNTPs, 1U of Taq polymerase (Qiagen, Hilden, Germany). The PCR was done on a 
MyCycler (BioRad, Germany) with the following thermal conditions: 94oC for 5 
minutes followed by 25 cycles of 94oC for 30 seconds, 55oC for 30 seconds and 72oC 
for 30 seconds, final annealing at 72oC for 10 minutes.  
The product of the pre-amplification PCR was used as the template for the nested 
multiplex Real-time PCR on a LightCycler 480 Instrument II using SensiMix™ II Probe 
Kit (Bioline GmbH., Germany) (27) following the manufacturer’s instructions. 
Sequences of primers and Pfcrt haplotypes specific probes are given in Table 4. Each 
sample was analyzed in duplicate. DNA of P. falciparum parasites of strains NF54, 
Dd2, and 7G8 were prepared from culture and used as positive controls for genotyping 
three haplotypes CVMNK, CVVIET, and SVNMT, respectively.  
3.6 msp1 genotyping 
3.6.1 Amplification of msp1 gene by conventional PCR 
Msp1 genes were genotyped by nested PCR using previously published pairs of primers 
(45).  
The conserved region of the msp1 gene was amplified in the primary PCR with a total 
volume of the reaction of 20µl consisting of 5µl of template, 15µl of master mix (which 
Table 3. Cycling conditions for 18S real-time PCR. 
Cycles Temp. Time Step 
1 96°C 10 min Polymerase activation 
45 95°C 62°C 
15 sec 
1 min 
Denaturation 
Annealing/Extension/Acquiring 
1 40°C 10 sec Cooling 
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contains 1x AmpliTaq Gold buffer, 1.5mM MgCl2, 0.25mM dNTPs, 1 U of AmpliTaq 
Polymerase and 250nM each primer). The PCR was performed using a MyCycler 
(BioRad, Germany) with the following thermal condition (27): 10 minutes at 94oC 
followed by 35 cycles of 94oC in 15 seconds, 58oC for 30 seconds, 72oC for 1 minute 
and 72oC for 10 minutes for the final extension. 
Nested PCR (27) amplified block 2 of the msp1 gene using 3 pairs of primers specific 
for 3 families of the msp1 gene: K1, MAD20, and RO33 (sequences of primers are in 
Table 4). Three nested PCR reaction mixes were made with the total volume of 20µl 
containing 2.5µl of template, other reagents were added at the same concentration as 
used in the primary PCR. Except for the annealing temperature was at 61oC, thermal 
conditions of the nested PCRs were similar to that of the primary PCR. P. falciparum 
strains NF54, Dd2, and 7G8 were used as positive controls for K1, MAD20, and RO33 
families of the msp1 gene, respectively. 
3.6.2 Amplicon sizing using capillary electrophoresis. 
Amplicon sizing by capillary gel electrophoresis was done on a QIAxcel Advance 
system (QIAGEN, Hilden, Germany) (27) according to the manufacturer’s instructions 
for the OM400 protocol. Each batch has 88 samples and 8 controls (7 positive controls 
and 1 non-template control). 
Materials: 
- QIAxcel DNA High Resolution Kits (catalog number: 929002).  
- QX DNA Size Marker 50–800 bp (50µl) v2.0 (Qiagen, cat.no. 929561) and,  
- QX Alignment Marker 15bp/1kb (Qiagen, cat. No. 929521).  
Amplicon size was analyzed by software QIAxcel ScreenGel v1.5.0 as described 
elsewhere (27). Data were analyzed and reported when positive controls were positive 
with a single peak (NF54: 241±3 bp, Dd2: 205±3 bp and 7G8: 153±3 bp).  A peak was 
defined as a countable allele when it was greater than 100 bp and contributed more than 
10% of total peak height. Within one sample, multiple peaks with less than 6 bp 
differences were considered as one allele and the average size was calculated and used 
for further analyses. 
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Table 4. Primer and probe sequences (27). 
msp1 
Primary PCR 
A AAGCTTTAGAAGATGCAGTATTGAC 
B ATTCATTAATTTCTTCATATCCATC 
Nested PCR 
K1 
Fwd AAATGAAGAAGAAATTACTACAAAAGGTGC 
Rev GCTTGCATCAGCTGGAGGGCTTGCACCAGA 
MAD20 
Fwd AAATGAAGGAACAAGTGGAACAGCTGTTAC 
Rev ATCTGAAGGATTTGTACGTCTTGAATTACC 
RO33 
Fwd TAAAGGATGGAGCAAATACTCAAGTTGTTG 
Rev CATCTGAAGGATTTGCAGCACCTGGAGATC 
Pfcrt 
 
Pre-amplification 
Fwd TGGTAAATGTGCTCATGTGTTT 
Rev AGTTTCGGATGTTACAAAACTATAGT 
RT-PCR 
Fwd TGGCTCACGTTTAGGTGGAGGTTCTTG 
Rev ACTGAACAGGCATCTAACATGGATATAGC 
Probes 
CVMNK TGTGTAATGAATAAAATTTTTGCTAA 
CVIET TGTGTAATTGAAACAATTTTTGCTAA 
SVMNT AGTGTAATGAATACAATTTTTGCTAA 
18S 
PCR 
PLU3 Forward GCTCTTTCTTGATTTCTTGGATG 
PLU3 Reverse AGCAGGTTAAGATCTCGTTCG 
PLU3 Probe VIC-ATGGCCGTTTTTAGTTCGTG-NFQ-MGB 
Red-highlighted letters represent the mutation points 
Fwd: forward primer 
Rev: reverse primer 
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3.7 Dual-probe endpoint genotyping (SNP barcoding assays) 
Primers and probe sequences used for this barcoding assays can be retrieved elsewhere 
(46). 
Table 5. Barcoding assays. Minor and major alleles were determined in the original 
work (46). 
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1 Pf_01_000130573 
 
C/T C  T  C  
2 Pf_01_000539044 
 
A/G A  G  G 
3 Pf_02_000842803 
 
T/C T  C  C 
4 Pf_04_000282592 
 
T/C T  C  T 
5 Pf_05_000931601 
 
G/C G  C  C 
6 Pf_06_000145472 rs45343635 C/G C  G  C 
7 Pf_06_000937750 
 
A/G A  G  G 
8 Pf_07_000277104 rs45339742 A/G A  G  G 
9 Pf_07_000490877 rs45343970 A/T A  T  A 
10 Pf_07_000545046 rs45338103 C/T C  T  C 
11 Pf_07_000657939 rs45403113 T/C T  C  T 
12 Pf_07_000671839 
 
A/G A  G  G 
13 Pf_07_000683772 rs45339189 C/T C  T  C 
14 Pf_07_000792356 rs45341962 A/C A  C  A 
15 Pf_07_001415182 rs45403212 C/A C  A  C 
16 Pf_08_000613716 rs45405749 C/A C  A  C 
17 Pf_09_000634010 rs45408065 C/T C  T  C 
18 Pf_10_000082376 rs45409692 A/T A  T  A 
19 Pf_10_001403751 rs45410415 A/C A  C  A 
20 Pf_11_000117114 rs45415497 G/A G  A  G 
21 Pf_11_000406215 
 
A/C A  C  A 
22 Pf_13_000158614 rs45422484 C/T C  T  T 
23 Pf_13_001429265 
 
G/T G  T  T 
24 Pf_14_000755729 
 
G/T G  T  G 
 
Master mixes was prepared following the instruction of the manufacturer for the 
TaqMan Universal PCR Master Mix (Applied Biosystems Catalog number 4364343). 
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Table 6. Master mix preparation for barcoding PCR. 
Component Volume for 1 reaction 
2x TaqMan Master Mix 2.5 µL 
20x Assay Working Stock 0.25 µL 
Template 2.25 µL 
Total volume per well 5 µL 
 
3.7.1 Preparation of the reaction plate. 
The DNA concentration of each sample and positive control were measured by 
NanoDrop Spectrophotometer. DNA was diluted to a similar concentration (1 ng/µl) 
across all samples before mixing with the prepared master mix on a 96-well PCR plate 
(LightCycler® 480 Multi-well Plate 96, white, Cat # 04729692001). 
3.7.2 Perform a PCR plate read  
Table 7. Cycling conditions for barcoding PCR. 
Step Temp Time No of Cycles 
Polymerase activation 95oC 10 minutes 1 
Denaturation 95oC 15 seconds 
40 
Annealing/extension 60oC 1 minute 
Cooling 40oC 30 seconds Hold 
Acquisition format as dual probe: VIC/HEX (excitation – detection: 533 – 580nm) and 
FAM (excitation – detection: 465 – 510nm). 
All of the PCR assays was done on a Light Cycler 480 Instrument II PCR system. The 
End-point genotyping result was analyzed and visualized using the built-in software 
LightCycler® 480 SW, version 1.5.1. 
3.8 Statistical analysis 
R software (version 3.5.1) was used to analyze all the data mentioned in this thesis and 
95% confidence intervals were given where possible. A two-sided p-value of <0.05 was 
considered statistically significant. 
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3.8.1 For work on RDTs (27)  
Cycle threshold (Ct) values were used in absolute quantification analyses to extrapolate 
parasitemia of the samples. The extrapolation was made in relation to Ct-values of a set 
of standard calibrators using linear regression analysis (with an assumption that equal 
amounts of blood (5 µl) were spotted on each RDT and calibrators).  
Positive PCR results were considered as negative (0 parasites/ml) if Ct values >40 and 
excluded from the analysis. Comparison of Ct-values of two serial dilutions: RDT and 
filter paper was done using a paired T-test. 
Individuals were stratified into three groups according to their age: (i) children <5 years 
(ii) children between 5 to 18 years and (iii) adults >18 years old and three groups based 
on their residence: Lambaréné (semi-urban), Fougamou (semi-urban) and surrounding 
rural areas (radius approximately 10km). 
The MOI was calculated for individuals and the population. For an individual, MOI is 
the sum of the number of alleles detected by msp1 genotyping (including 3 gene 
families): 
 
MOI = number of K1 allele + number of MAD20 allele + number of RO33 allele 
 
Population MOI was the mean MOI of all individuals and calculated by dividing the 
total of individual MOI by and the total number of PCR positivity. Sample with MOI = 
1 was considered as a monoclonal infection the other positive samples were considered 
as polyclonal infections. 
MOI parameters were displayed as mean numbers, but while comparing MOI between 
age or location groups, the non-parametric Kruskal-Wallis H and Wilcoxon rank-sum 
tests were used. The decadic logarithm (Log10) of parasite densities were compared 
between age groups using these tests.  
Linear and logistic regression models were used as shown in Table 8. In all models, 
location as an independent variable was defined based on different population density: 
rural areas, Fougamou and Lambaréné. The relation between age and Log10 
transformed parasite density was analyzed by a linear regression model.  
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Table 8. Regression models used. 
Test Dependent variable Independent variables 
Poisson regression model MOI age, location 
Binomial regression model CQ resistance age, location 
PCR success storage duration 
Linear regression model Log10 parasitemia age 
 
3.8.2 For SNP barcoding assays 
Minor allele frequency was calculated for each SNP as previously described (49). In 
brief, each allele found in a polymorphic genotype was considered to contribute a half 
of an allele found in a monomorphic genotype. Allele frequency was calculated for each 
SNP using allele counts. 
A new infection is defined when the parasite genotype at day X (day of recurrence) has 
at least 1 distinct SNP compared to the genotype of day 0 (admission). Therefore, only 
monomorphic SNP result was used to distinguish parasite genotypes. 
3.8.3 For work on SMA samples 
The recruitment process allocated patients into three groups based on Hb concentration, 
but in data analysis, patients were classified as severe malarial anemia (SMA) if RBC < 
2.8 Mio/ml, and moderate malarial anemia (MM) if RBC >2.8 Mio/ml regardless of Hb 
concentration. 
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4 RESULTS 
4.1 Performance of RDTs as source of DNA for molecular assays 
4.1.1 Demographic details of uncomplicated malaria and asymptomatic P. 
falciparum parasitemia 
A total of 669 positive RDTs were collected from uncomplicated malaria and 
asymptomatic P. falciparum parasitemia including 332 (50%) female. The median age 
was 8 years (Interquartile Range - IQR: 4-15). 185/669 (28%) were children aged under 
5 years, 346 (52%) between 5 and 18 years and 138 (21%) aged >18 years. 125 (18.7%) 
samples were collected from Lambaréné and from rural areas, 122 (18%) were from 
Fougamou and 422 (63%) from other rural areas Table 11. The mean storage duration 
was 113.2 days (range: 9 – 231 days).  
4.1.2 Success rates of different PCRs using DNA extracted from RDTs 
Using positive RDTs as a source of DNA for 18S quantification real-time PCR, Pfcrt 
PCR, and msp1 genotyping PCR, RDTs produced 96.6%, 87.4%, and 88.5% 
amplification success rates, respectively (Table 9). Longer storage duration of RDTs 
did not change the amplification success rate of 18S PCR notably. 
Table 9. Proportion of positivity of molecular assays using DNA extracted from RDTs 
(27).  
 
Time of sample storage 
 
<1 month 
(N = 138) 
1-3 months 
(N = 57) 
3-6 months 
(N = 361) 
>6 months 
(N = 113) 
Total 
(N = 669) 
Assay 
     
18S PCR 135(97.8%) 52(91.2%) 353(97.8%) 106(93.8%) 646(96.6%) 
Pfcrt PCR 120(87%) 49(86%) 314(87%) 102(90.3%) 585(87.4%) 
msp1 PCR 112(81.2%) 52(91.2%) 322(89.2%) 106(93.8%) 592(88.5%) 
N: sample size 
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Table 10. Lower limit of detection of PCR protocols using DNA extracted from RDT. 
Parasitemia (p/mL) 18S RT-PCR Pfcrt  PCR msp1 PCR RDT 
6840000 + + + + 
684000 + + + + 
68400 + + + + 
6840 + - + - 
684 + - - - 
68 + - - - 
 
4.1.3 For quantification of parasite density by 18S PCR 
4.1.3.1 RDTs versus FP 
Two serial DNA dilutions were made from 6 RDTs and 6 circles of filter paper.  
Absolute quantitative real-time PCR targeting 18S genes were run in triplicates. Ct-
values were used to analyze the performance of these two DNA sources. All samples of 
these series including the lowest parasitemia (68 parasites/ml) were positive. Ct-values 
of two groups of samples RDT and filter paper were similar (Figure 5). 
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Figure 5. Comparison of the performance of RDTs and FPs as source of DNA for 
quantitative real-time PCR. A: The correlation between Ct-values and peripheral 
parasitemia: RDT (red) and filter paper (blue). The PCRs were performed for each 
sample in triplicate and the means of Ct-values were represented by these dots. The 
straight lines visualized the linearity between the mean Ct-values and decadic logarithm 
transformation of parasitemia of the RDT group (red, adjusted R2: 0.9944) and FP 
group (blue, adjusted R2: 0.9892) (27). B: The Bland Altman plot visualized the 
agreement between the Ct-values of PCRs which were performed using two types of 
samples, red line: mean of differences, blue lines: 95% confidence intervals of the 
differences. The positive difference between the Ct values of the RDT group and the FP 
group implied that the DNA load extracted from RDT was lower than that from the FP, 
but the difference was not significant. 
4.1.3.2 Parasitemia in uncomplicated malaria and asymptomatic P. falciparum 
parasitemia 
Extrapolated parasitemia from Ct values of PCRs (using the linear model mentioned in 
4.1.3.1) was excluded from analysis if lower than 1 p/mL. Parasitemia in the group of 
children aged <5 years (geometric mean: 3548 parasites/mL (95% CI: 2188 – 4677)) 
was significantly higher than that in the other two age groups: 5 to 18 years and >18 
years, with geometric mean of parasitemia of 1259 (95% CI: 891 – 1698) and 776 (95% 
CI: 457 – 1318) parasites/mL, respectively (Figure 6).  
A B 
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Figure 6. Parasitemia in different age groups of uncomplicated malaria and 
asymptomatic P. falciparum parasitemia. The significance levels: significant (***: 
<0.001, ****: <0.0001) and nonsignificant (ns) (27). 
 
4.1.4 For assessment of diversity of P. falciparum 
4.1.4.1 Capillary electrophoresis and visualization of allele size by QIAxcel 
Figure 7. An example of the msp1 genotyping result. Graphs 1,2 and 3 represent CE 
results of msp1 families RO33, MAD20, and K1, respectively. Each peak (except the 
ones with the sizes of 15bp and 1000bp – which are size markers) shown in this graph 
represents one single allele (strain). MOI of the sample was 5.    
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4.1.4.2 MOI in association with age and region 
The highest individual MOI was 11. The MOI of the population was: 2.6 (95% CI: 2.5 -
2.8). The MOI was higher in groups of ages <5 years (2.8 (95% CI: 2.6-3.1)) and 5 to 
18 years (2.7 (95% CI: 2.5-2.9)) than in group of ages >18 years (2.1 (95% CI: 1.9-
2.4)). MOI for samples from Lambaréné was 2.0 (95% CI: 1.8-2.3), significantly lower 
than Fougamou 2.8 (95% CI: 2.5- 3.1) and rural areas 2.8 (95% CI: 2.6- 2.9) (Figure 8). 
Poisson regression model confirmed the significant adverse association of both age and 
location and MOI (age: β = -0.0046, p-values = 0.019 and location: β =-0.314, p = 
0.0004) . 
The prevalence of monoclonal infection observed in LA was lower than that in the 
regions (df = 2, p-value = 0.004). 
 
Figure 8. MOI across studied regions (A) and age groups (B)(27). MOI was displayed 
as the number of alleles per individual in y-axis. Box plots were shown with medians 
and interquartile ranges (IQR). In order to avoid overlapping, each number of alleles 
per individual (countable number) was visualized by a  jitter point. The significance 
levels were: significant (***: <0.001, ****: <0.0001) and nonsignificant (ns). RR: 
rural areas, FGM: Fougamou, LA: Lambaréné. 
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4.1.4.3 Prevalence of msp1 alleles in uncomplicated malaria and asymptomatic P. 
falciparum parasitemia 
Five hundred ninety five samples were positive with msp1 genotyping PCR, the 
prevalence of three msp1 gene families were K1: 75% (n=446); MAD20: 47% (n=275); 
and RO33 51% (n=305).  
A total of 27.5% (n=163) of the msp1 PCR positive isolates were monoclonal infections 
(Table 11). msp1/K1 alleles were found in the major proportion of monoclonal 
infections, whereas msp1/ K1 + RO33 and K1 + Ro33 + MAD20 alleles were more 
commonly observed in polyclonal infections (Table 11). The allele sizes for each of the 
families of the msp1 gene were 133 - 374 bp (K1), 133 - 311 bp (MAD20) and 111 - 
258 bp (RO33) (Figure 15). There was no specific allele for any age group or region.  
 
Table 11. msp1 PCR positivity and the distribution of msp1 genotypes in 
uncomplicated and P. falciparum asymptomatic infection across geographic regions 
(27). 
 
FGM LA RR Total 
N (%) 122(18.2) 125 (18.7) 422 (61.3) 669 
msp1 PCR positivity (%) 111 (18.7) 107 (18.1) 374 (63.2) 592 
Monoclonal infection 24 (21.6) 43 (40.2) 96 (25.7) 163 (27.5) 
Polyclonal infection 87(78.4) 64 (59.8) 278 (74.3) 429 (72.5) 
K1 only 18 40 88 146 
MAD20 only 10 15 31 56 
RO33 only 11 14 39 64 
K1 + MAD20 14 10 61 85 
K1 + RO33 24 17 66 107 
MAD20 + RO33 8 4 14 26 
K1 + MAD20 + RO33 26 7 75 108 
 
4.1.5 For genotyping CQ-resistant P. falciparum  
The overall prevalence of CQR genotypes in the study population was 78.5%. 
Prevalence of CQ sensitive genotypes in the group of children aged <5 years was 26%, 
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followed by 48% of CVIET genotype (CQR) and 27% of mixed infection with sensitive 
and CQR genotypes Table 12. The prevalence of these genotypes (sensitive, CVIET 
and mixed strains) in other two age groups was: 18.8%, 44.2%, and 37%, for the group 
aged from 5 to 18 years, and 22.6%, 47.0%, and 30.4% for adults, respectively (Figure 
9).  
The prevalence of CQ resistant genotypes was not significantly different between three 
age groups (p-value = 0.2). The prevalence of CQR genotypes in Lambaréné (65.7%) 
was lower compared to that of the rural areas (Fougamou and other rural areas – 81.3%) 
(p-value = 0.0017) Table 12. Logistic regression analysis showed an association 
between living in Lambaréné and lower prevalence of CQR genotypes of P falciparum 
(β = - 0.809,  p-value = 0.011 after correction for age). 
 
Table 12. Prevalence of Pfcrt haplotypes, age distribution and msp1 genotyping result 
across regions (27). 
  FGM LA RR Total 
N (%) 122(18.2) 125 (18.7) 422 (61.3) 669 
Age     
≤ 5 years (%) 23 (18.8) 24 (19.2) 138 (32.7) 185 (27.7) 
≥ 5 to 18 years (%) 80 (65.6) 58 (46.4) 208 (49.3) 346 (51.7) 
Adults (>18 years) (%) 19 (15.6) 43 (34.4) 76 (18.0) 138 (20.6) 
Pfcrt-PCR positivity (%) 109 (18.6) 108 (18.5) 368 (62.9) 585 
CQ sensitive (CVMNK) only (%) 21(19.3) 37(34.3) 68(18.5) 126 (21.6) 
CQ resistance 1 (CVIET) only (%) 43 (39.4) 50(46.3) 174(47.3) 267(45.6) 
CQ resistance 2 (SVMNT) (%) 0 0 0 0 
Mix (R and S) (%) 45(41.3) 21(19.4) 126(34.2) 192(32.8) 
 
Regional prevalence of CQ resistance (by summing up the prevalence of resistance and 
mix infection) was 65.7% in LA and 81.3% in rural areas (including FGM and other 
rural areas). R: chloroquine resistance; S: chloroquine-sensitive; FGM: Fougamou; LA: 
Lambaréné; RR: rural regions, CQ: chloroquine 
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Figure 9. The prevalence of Pfcrt haplotypes was similar between age groups. Mix 
infections: infected by both sensitive and resistant genotypes of P. falciparum. SVMNT 
haplotype was absent in this population (27). 
4.2 Performance of the barcoding assays 
4.2.1 Validation of the SNP barcoding assays 
The 24-SNPs barcoding assays successfully genotyped 6 in vitro cultured well-
defined laboratory P. falciparum strains: 3D7, Dd2, HB3, 7G8, W2, D10. The 
fluorescence signal was automatically analyzed by the software and visualized in a 
scatter plot, followed by manual allele calling. 
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Figure 10. An example of the genotyping result of P. falciparum strain 3D7 together 
with a non-template control and a field sample. A scatter plot was generated by the 
built-in software using the protocol of end-point analysis. The signal intensity of two 
florescent dyes was measured and plotted; green dots represent major alleles only 
which were labeled with VIC dye (in y-axis, with florescence excitation 533nm and 
detection 580nm), blue dots for minor alleles only which were labelled with FAM 
florescence (x-axis, excitation: 465nm and detection: 510nm) and red dots represent 
both alleles. 
For monoclonal samples (e.g. cultured lab strains), distinct clusters were shown in 
the scatter plot (as green and blue dots only), and allele calling is determined visually 
from the plot. 
A total of 8 field isolates collected from Gabon were genotyped to estimate the 
complexity of infection. Three out of eight (37.5%) samples were monoclonal whereas 
5 out of 8 (62.5%) samples were polyclonal. Sample J12 appeared to be the most 
complex infection since 10 out of 24 SNPs were polymorphic. 
4.2.2 Limit of detection of minor strain in mixed infection 
The assay for SNP C/T on chromosome 13 at position 000158614 was done for the 
serial dilutions of a mix of two parasite strains: 3D7 and Dd2. All 7 dilutions were 
genotyped.  
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Figure 11. The plot of 1 SNP genotyping of serial samples created by mixing DNA of 
2 P. falciparum lab strains (3D7 and Dd2) with different ratios. The location of red 
dots on the scatter plot reflex the mixing ratio of two parasite strains 3D7 (allele C) and 
Dd2 (allele T). NTC: non-template control. 
Table 13. Concentration of parasite DNA in the serial dilution and sensitivity of assay 
Pf_13_000158614. SNP gen: SNP genotyping result. 
Name of sample A-2 A-1 A1 A2 A3 A4 A5 A6 A7 A8 A9 
3D7/Dd2 DNA ratio 16:1 10:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:10 1:16 
Concentration 
(ng/µL) 
3D7 9.4 9.1 8.9 8.0 6.7 5.0 3.3 2.0 1.1 0.9 0.6 
Dd2 0.6 0.9 1.1 2.0 3.3 5.0 6.7 8.0 8.9 9.1 9.4 
SNP gen for 3D7 (C) + + + + + + + + + NA NA 
SNP gen for Dd2 (T) NA NA + + + + + + + + + 
 
Genotyping results of the samples with mixing ratios greater than 8:1 and smaller than 
1:8 showed that minor alleles cannot be reliably discriminated when they contribute less 
than ~12.5% of the major alleles density in the same sample.  
4.2.3 Discrimination between recrudescence and new infection 
Seven pairs of samples collected from a drug efficacy trial in Gabon were successfully 
genotyped. There were 6 out of 7 (85.7%) samples classified as new infections, 1 out of 
7 (14.3%) was not classifiable due to the too high complexity of both samples (Day 0 
8:1 
4:1 
2:1 
1:1 
1:2 
1:4 
1:8 
Assay: 
Pf_13_000158614 
(C/T) 
NTC 
VIC 
Allele: C  
FAM 
Allele: T 
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and Day X). SNP 15 was excluded from our analysis since all of the PCR results were 
negative.  
4.2.4 Establishment of a minimal SNP barcode 
Table 14. Genotyping result of 21 samples at 9 SNP loci. Minor allele freq: Minor 
allele frequency.  
SNP 5 6 7 9 10 11 13 14 22 
  
Allele variants G/C C/G A/G A/T C/T T/C C/T A/C C/T 
F078_SCR C C A A U T C A C 
F079_D42 C C G A C T C A C 
F079_SCR C G U A C T C C T 
F080_D35 U C A A C U   C C 
F080_SCR G C G T T T   A T 
F081_D35 C C G A C T T C C 
F081_SCR U G G T C U   C T 
F090_D63 U U G A C C   C C 
F090_SCR C C A U C T C A T 
F095_D42 G C A U T T T A C 
F095_SCR G C A T C T C C C 
F098_D63 C G A A T T C A T 
F098_SCR C C U T C T C C U 
J11 G G A T T C C C C 
J12* U C U T U C C A T 
J13 C G G T U U   C C 
J14 G C A T T C T A C 
J20 G C A T C C C A T 
J23 G C G T T C T A T 
J25* U U U A C T C C T 
J3S G G A T U T C A C 
Minor allele freq 0.5 0.341 0.432 0.432 0.386 0.364 0.263 0.477 0.455 24-SNPs 
barcode Amp success rate (%) 100 100 100 100 100 100 86.4 100 100 
Uniqueness calling 90.50% 90.50% 
 
Amp success rate: amplification success rate. *: samples with non-unique SNP barcode. 
A: Adenine; C: Cytosine; G: Guanine; T: Thymine; U: mix of two alleles; blanks: 
amplification failed. Sample F078_D42 was excluded from this analysis due to the 
negative result at 5/9 SNPs. 
A compiled analysis using the sample from all experiments showed the minor allele 
frequency (MAF) of the 24 SNPs ranged from 0.02 to 0.5. 
Based on MAF (>0.25) and amplification success rate (>80%), 9 assays number 5, 6, 7, 
9, 10, 11, 13, 14, 22 were selected for a minimal barcode. The minimal barcode showed 
similar discriminatory power to the 24-SNPs barcode (Table 14). 
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4.3 P. falciparum in peripheral blood and bone marrow of anemic malaria 
4.3.1 Parasitemia  
4.3.1.1 Between BM and PB 
A total of 91 thick blood smears (TBS) made from peripheral blood samples were read. 
The mean of log10 transformed parasitemia was: 4.35 (95% CI: 4.20, 4.50). 
Ct values from PCR using bone marrow samples are significantly lower than those 
using peripheral blood samples ([Paired t.test] p-value < 0.0001). 
 
 
 
 
 
 
 
 
 
Figure 12. Bland Altman plot visualizes the agreement of the Ct-values of PCR using 
peripheral blood (PB) and bone marrow (BM). The green lines represent 95% 
confidence intervals. Y-axis: the difference between Ct-values of PCR using PB samples 
and BM samples from the same patient. The blue line represents the mean of the 
differences. The difference in Ct values between PB and BM samples was negative in 
100% severe malarial anemia cases whereas in the group of non- and mild anemia, the 
positive differences were observed in some samples. 
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Figure 13. The correlation between the Ct-values of qPCR and TBS results. Y-axis 
represents the average Ct-values of triplicate PCR. 
There are significant correlations of Ct values and microscopic parasitemia. With bone 
marrow samples: p-value = 0.00032, Adjusted R2: 0.2355 and peripheral blood 
samples: p-value < 0.0001, adjusted R2: 0.5759 (Figure 13). 
The results from a binomial regression model showed that anemia was independent of 
parasitemia assessed by PCR using bone marrow samples as well as peripheral 
microscopic TBS results.  
4.3.1.2 Between SMA and MM 
Peripheral parasitemia between SMA group (Log10 parasitemia = 4.34 (95% CI: 4.07, 
4.61)) and MM group were similar (Log10 parasitemia = 4.35 (95% CI: 4.19, 4.52)), p-
value = 0.93. 
4.3.2 Multiplicity of infection 
4.3.2.1 Different MOI between BM and PB of the same patient 
MOI of the parasite populations in bone marrow was 3.06 (95% CL: 2.69, 3.44) and in 
peripheral blood was 3.11 (95% CL: 2.70, 3.51). There was no difference observed 
between MOI of the parasite population in these two compartments, the result was 
confirmed by a binomial regression model.  
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The difference in the number of alleles was observed in 8/47 pairs (17%) of the sample 
(from 08 patients).  
 
Figure 14. Agreement of genotyping result using bone marrow samples (MOI_BM) 
and peripheral blood samples (MOI_PB). X-axis: average MOI of 2 types of samples 
from the same patients, y-axis: the difference between MOI of 2 types of samples. 
Flower patterns: represent the number of identical results. 
In 8/8 pairs of samples, the discordant alleles (the one detected in 1 type of sample but 
was not detected in the other type sample) were minor alleles. 
4.3.2.2 MOI was not a predictor of anemia and blood transfusion 
MOI of the group of SMA was 3.12 (95%CI: 2.54, 3.70), and was not different from 
that of the MM group 3.10 (95%CI: 2.55, 3.65), p-value = 0.57 (Wilcoxon test) 
MOI of the group of patients with blood transfusion was 2.88 (95% CI: 2.33, 3.44) and 
was not different from that of the group without blood transfusion (3.17 (95% CI: 2.67, 
3.66)), p-value = 0.72. The result was also confirmed by a binomial regression model. 
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4.3.3 msp1 allele prevalence in MM and SMA 
 
Figure 15. The distribution of allele size among the groups of patients with SMA and 
MM. There was no msp1 allele that is specific for any of the level of severity of anemia. 
 
Table 15. Combination of msp1 genotypes in anemic malaria cases. 
 
Anemia  
Mild (N = 30) Severe (N = 17)  
BM (%) PB(%) BM(%) PB(%) 
K1 only 13 (44) 14 (47) 2 (12) 3 (18) 
MAD20 only 3 (10) 3 (10) 0 0 
RO33 only 1 (3) 1 (3) 2 (12) 2 (12) 
K1 + MAD20 7 (23) 7 (23) 5 (29) 3 (18) 
K1 + RO33 3 (10) 3 (10) 5 (29) 5 (29) 
MAD + RO33 0 0 0 0 
K1 + MAD20 + RO33 3 (10) 2 (7) 3 (18) 4 (23) 
Total 30 (100) 30 (100) 17 (100) 17 (100) 
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5 DISCUSSION 
5.1 RDTs are excellent source of DNA for large scale investigational studies 
Archived RDTs are a reliable source of DNA for Realtime PCR and the amplification 
success rate is comparable to that achieved from filter paper (27,41). PCR using DNA 
extracted from both sources could detect Plasmodium parasites at as low density as 68 
parasites/mL. The yield of DNA recovered may vary among different designs of RDT. 
Lower DNA yield was reported for RDT types that have a plastic cover on top of the 
nitrocellulose strip (40). The limit of detection and success rate of molecular assays 
using DNA extracted from RDT also rely on the extraction methodology (41) and, 
better result was achieved by using commercialized column-based kits. Besides, 
absolute quantification of malaria parasites using archived RDT samples is possible, 
which expands the contribution of RDT to the success of field studies. However, the 
accuracy of the quantification process can be influenced by the ununiformed blood 
volume spotted on RDT (69). The extrapolated parasitemia in this work, therefore, 
served only the analyses with the assumption that blood volumes on every RDT were 
identical (both on the field RDT and controls). The storage duration (within 6 months at 
room ambient) of archived RDTs did not interfere with either DNA quality or the 
amplification success rate (27).  
The sensitivity and specificity of quantitative real-time PCR which targets 18S genes 
(especially multiple copy genes as the approach used in this thesis) were demonstrated 
to be higher compared to that of other conventional methods. Additionally, parasite 
density in uncomplicated and asymptomatic P. falciparum parasitemia is usually low 
and is often undetectable by microscopy. Therefore, the amplification success rates of 
msp1 genotyping PCR and Pfcrt (single-copy gene) genotyping PCR are often relatively 
lower than that of our 18S-targeted real-time PCR.  
RDTs are used to detect parasite-specific antigens (hrp2, lactate dehydrogenase and 
aldolase) which were demonstrated to circulate in human blood even after parasites are 
removed, therefore, RDT may still show a positive result in some transient infections 
for days after parasite clearance. That reason, together with the absence of negative 
RTD in the analyses may explain the amplification failure rates observed in this work. 
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In line with results from previously published work, we demonstrated that being able to 
provide a diagnosis in minutes and serve as a source of DNA for molecular testing, 
malaria RDTs could potentially represent the key of large scale retrospective analyses of 
parasite populations (27).  
5.2 The pattern of parasitemia in study populations in Gabon 
Age and exposure to malaria parasites are described as two major factors that define the 
risk of developing parasitemia and illness. Both age and exposure to malaria were found 
to induce and regulate the host immunity to malaria. When analyzing the effect of each 
factor independently on the immune response to the first malaria episode between 
children and naïve adults, the result surprisingly showed that the effect of age alone was 
small, and the main determinant was malaria exposure (70). Often, these two factors 
correlate, especially in malaria-endemic regions, therefore, higher parasitemia is 
observed in children more often than in adults (71). 
In children aged from 9 months to 5 years, results from TBS has revealed that, except 
for immature gametocytes density and prevalence, asexual and matured parasite density 
in bone marrow samples and peripheral blood was similar (15). Since TBS from bone 
marrow samples were not made in this study, we analyzed Ct-values from the qPCR 
results to compare the DNA load between samples. The extrapolation from Ct-values to 
parasitemia in bone marrow might result in an imprecise estimation because most of the 
mature parasites e.g. trophozoites and schizonts are accumulated in bone marrow (15), 
each of them contains often more than one genome. By PCR, the parasite DNA 
concentration (regardless of the stage of the parasite, represented by Ct-values) in 
peripheral blood was revealed to be slightly higher than that in bone marrow samples 
(Figure 12).  
The comparison might be additionally biased due to the fluctuation of peripheral 
parasitemia. In fact, parasites at mature stages and gametocytes were found in bone 
marrow while absent in the periphery as described in a case report (72). In our study, the 
number of asexual parasite count in TBS partly but significantly correlates with the Ct-
values from PCR using peripheral blood as well as bone marrow samples.  
In line with results from the previous study which emphasized the role of lysis of non-
parasitized RBC in the pathogenesis of malarial anemia (26), in this study population, 
peripheral parasitemia (from TBS reading) and Ct-values of PCR using bone marrow 
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samples are not predictors of severity of anemia. That implies that admission 
parasitemia is a poor predictor of malarial anemia and, suggests to further look into the 
other characteristics of the infection e.g. parasite diversity. 
5.3 msp1 genotyping revealed high diversity of P. falciparum parasite in Gabon 
5.3.1 Automated CE enhances the resolution of conventional-PCR-based 
genotyping. 
Approaches used to estimate the diversity of the malaria parasite populations are still 
basing on conventional PCR, and the ones targeting the length-polymorphic genes have 
been commonly used. The performance of these approaches relies mainly on the 
resolution of the sizing system and could be enhanced by using capillary electrophoresis 
(27).  
Our study was the first in Lambaréné – a field site of numbers of malaria-related trials – 
to use QIAxcel Advanced System – the high resolution, automated capillary gel 
electrophoresis to analyze the population genetic diversity of P. falciparum (27). This 
system provides a high discriminatory power (three base-pairs difference) and is able to 
detect up to 11 alleles in one infection. Such an automated system allows for sizing 
analysis of batches of 96 samples in one run. The outcome could be used for different 
analyses in order to characterize the malaria parasite, including the length of the 
amplicons, identification of major and minor alleles, and the relative proportion of each 
allele. Despite a lower resolution of this system compared to that of sequencers when 
genotyping short tandem repeats (microsatellites) (73,74), this system could be a part of 
a field-deployable approach for genotyping other marker genes (like msp genes) with 
higher accuracy compared to conventional gel electrophoresis. 
5.3.2 Parasite diversity in uncomplicated malaria and asymptomatic P. 
falciparum parasitemia 
P. falciparum merozoite surface protein 1 (MSP1) involves the invasion process of 
these parasites into the human erythrocytes. Studying the polymorphism and the 
fluctuation in the diversity of this important gene in malaria-endemic areas may help 
understanding selection pressure. Indeed, patterns of the multiplicity of malaria 
infections were shown across age groups and geographic regions, thus, a high 
polymorphism of the msp1 gene in the studied population has been recorded (27).  
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The population MOI was 2.6 (2.0 for Lambaréné and 2.8 for Fougamou and rural areas), 
which is in line with results from recent reports (75). That implies the decrease in the 
complexity of malaria infection as compared to what was observed in 2000 (76) – 
before ACTs became the first-line therapy.  
Immunity against malaria is acquired after exposure to P. falciparum parasites, 
therefore, it relates to transmission intensity and age of individuals. As a result, parasite 
diversity is often lower in adults than in children. After correction for the effect of age, 
the result showed a significant correlation of difference in the geographic location on 
MOI. In regions with higher economic status, it is possible that drug pressures can cause 
fluctuation of parasite clones in patients, results in disappearance or reappearance of 
some parasite strains (76).  
The MSP1, particularly transcription of msp1/K1 and MAD20 gene families have been 
highlighted as potential targets for P. falciparum vaccine development (77). In this 
study, the prevalence of msp1/K1 was predominant, followed by msp1/RO33 and 
msp1/MAD20 families. However, there were no specific alleles for any region or age. 
This result is in line with that from other studies conducted in different lab settings and 
geographic regions (76,78). P. falciparum allele size of around 240 bp was the most 
prevalent (26.7%), that size is similar to the length of the msp1 gene of strain NF54 (241 
bp) – which is the parasite strain used in some clinical trials in Lambaréné (27).  
5.3.3 P. falciparum diversity in BM and PB of patients with malarial anemia 
At the population level, similar to what is observed in the placenta and umbilical cord 
blood (20), MOI of the parasite in bone marrow is similar to that in peripheral blood.  
In severe malaria patients, a higher prevalence of msp1/MAD20 alleles (10) or msp1/K1 
alleles (9) was observed. In our study, the prevalence of P. falciparum msp1/K1 and 
msp1/K20 alleles in monoclonal infections was higher in mild and non-anemic malaria 
group. There was no association between the prevalence of other alleles and anemia. In 
addition, there is no specific allele size for severe malarial anemia. Prevalence of msp1 
alleles in the population and their contribution to the severe form of malaria may change 
over time due to selection pressure. Causing mild and asymptomatic malaria may be a 
useful strategy for the malaria parasite to improve fitness costs since mild and 
asymptomatic malaria cases are demonstrated to be the main source of transmission. 
The difference in the prevalence of some alleles of msp1 genes in this study population 
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over time (our result compared with the result of Kun et al 1998) may reflect the 
ongoing change within the parasite population which is probably due to selection 
pressure. The finding highlighted the need for the frequent monitoring of malaria 
parasite in endemic regions. 
In a significant proportion of patients (17%), the number of parasite strains identified in 
the bone marrow differs from that in peripheral blood. The difference in the observed 
MOI between peripheral blood and bone marrow might be the result of the within-host 
competition (11) – in which, resource competition may lead to the suppression of some 
minor parasite strains – or the interaction between parasite and host’s immunity. 
The limitations of this analysis were: first, the small sample size since the initial study 
design was not for this purpose and second, the effect of the geographic factor was not 
corrected as in the work with uncomplicated malaria and asymptomatic P. falciparum 
parasitemia we have demonstrated that the difference in MOI could also be observed in 
different regions and age groups. 
5.4 A minimal SNP barcode for genotyping P. falciparum in Gabon 
The primary goal of this work was to validate the established SNP “barcode” for 
genotyping P. falciparum in our lab setting and optimize the barcode to a number of 
SNPs that are specific for the malaria parasite in our studied area and allow high 
throughput.  
Regardless of the genotyping method, the distinction between new infections and 
recrudescence remains difficult, especially in highly complex infections. Although 
minor strain which consists of a negligible proportion of total parasite load should not 
affect the treatment outcome, the definition or the cut-off values by which the minor 
strains are defined is still not well characterized. It depends on the techniques used and 
the author’s preference. The most general cut-off is around 20% for conventional 
methods (79) (parasite strain consists lower than 20% of the overall parasite load should 
be considered negligible) or could be 10% for more advanced methods (80). With SNP 
barcoding assay, the genotyping result of samples that contain 1 or 2 parasites strains 
was displayed in colors in a scatter plot, therefore the interpretation can be done with 
bare eyes. However, in poly-genomic infections, where the difference in parasite density 
between major and minor alleles is large (minor alleles density are less than ~12.5% of 
the overall parasite load), the identification of alleles becomes more complicated. One 
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drawback of this genotyping approach is the genotype calling process for complex 
infections (when both minor and major alleles are detected in the greater number of 
SNP) since the rearrangement and estimation of all the SNP result relies (if exists) on 
analyses that use many assumptions (81).  
The entire barcode was developed using sequence data from 18 isolates collected from 
different endemic regions, 5 out of these 18 were from Africa (82). The barcode is 
robust when using 24 most polymorphic SNPs that are able to distinguish parasites with 
high predictive accuracy. However, using all 24 SNPs for the work in one geographic 
region is not necessary. To this point, a smaller but powerful barcode is of our interest. 
Here, we described a minimal barcode consisting of 9 SNPs that showed a similar 
discriminatory power to that of the entire 24-SNPs barcode. The amplification success 
rate was shown to be different between the SNP assays, even when applied to the same 
sample, therefore the sensitivity of the whole barcode assays should not be represented 
by the lower limit of detection of any of the 24 SNP assays. In addition, besides the 
ability to give results after a one-step-PCR and without using any sizing or imaging 
analysis, the SNP barcoding assays were shown to have comparable performance in 
distinguishing parasite strains to msp method (56). More important, minimizing the 
number of SNP assays can reduce the cost of this method (56).  
Another possible application of this method could be to differentiate parasite clones 
used to test the efficacy of vaccine candidates against heterozygous challenges since 
identified strains could be distinguished by using one or two SNPs. 
This work had some limitations. First, the number of samples used to validate and 
analyze the discriminatory power of the barcode was small. Second, the number of SNP 
of the minimal barcode remains unsatisfactorily high (9 SNPs). Therefore, validating 
the barcode assay using a bigger number of samples will potentially result in a better 
selection of SNP assays.  
5.5 Prevalence of CQ-resistant haplotypes in Gabon remains high 
In Gabon, chloroquine has been replaced by artemisinin-based combination therapies 
(ACTs) in 2005, these drug combinations became the first-line regimens for the 
treatment of uncomplicated malaria since then. Before this change, the prevalence of the 
CQ resistance-related genotypes was close to 100%. A few years after the change in 
national guidelines, several studies have documented a regional reduction in the 
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prevalence of CQ-resistant alleles (83,84). Another study has documented a low 
prevalence of the CQ-susceptible wild-type haplotype CVMNK in samples collected 
during 2011 –  2014 (85). A recent study conducted in rural Gabon has concluded a 
high (89%) overall prevalence of CQR genotypes (3). Although the use of amodiaquine 
was connected with the persistence of a high prevalence of CQR genotypes, strong 
evidence is scarce.  
The prevalence of CQ-resistant haplotypes in Lambaréné was found to be lower than 
that in Fougamou and rural areas. The prevalence of CQ-resistant haplotypes is 
independent of age. All of the isolates carry CQ-resistant haplotype CVIET (triple 
mutation at codons 74, 75 and 76), haplotype SVMNT (double mutation at codons 72 
and 76) was not found (27). These findings highlight the necessity of further 
investigations to better understand the mechanism behind the persistence of CQ 
resistance. 
5.6 Conclusion 
Rapid diagnostic tests are the multifunctional tool for field studies on P. falciparum. 
Besides the great contribution to the success of treatment and management of malaria 
by giving the prompt diagnosis, RDTs are also a good source of DNA for molecular 
assays that aim at genotyping malaria parasites and possibly parasite quantification. The 
resolution of the conventional msp1-gene-targeted PCR-based genotyping method was 
enhanced by CE on an affordable and automated system. The minimal but specific SNP 
“barcoding” assays for discrimination of  P. falciparum strains from Gabon has been 
established. Using these tools, high diversity and prevalence of CQ-resistant haplotypes 
of P. falciparum are observed in Lambaréné – Gabon, and proximity. Additionally, the 
parasite population structure has been shown to be different across age groups, 
geographical regions and occasionally between peripheral blood and bone marrow of 
one individual, however, the association between parasite diversity and severity of 
malarial anemia was not found.  
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SUMMARY 
Understanding the population structure of malaria parasites and the host-parasite 
interaction is of fundamental interest and may help in the development of improved 
anti-malarial interventions. This thesis contributes to the improvement of procedures 
and methods for the characterization of the malaria parasite and reports current 
epidemiological characteristics of Plasmodium falciparum populations in Lambaréné, 
Gabon.  
The result of this thesis encourages the use of rapid diagnostic tests (RDT) not only as a 
diagnostic tool but also as a source of DNA that can be subsequently used for molecular 
assays to assess parasite diversity, species distribution,  and genetic polymorphisms 
(e.g. mutations associated with drug resistance) as well as diagnostic performance of 
RDTs on large scale. In addition, performance and resolution of a genotyping method 
based on size polymorphisms of the msp1 gene, by using conventional polymerase 
chain reaction (PCR) followed by automated capillary electrophoresis (CE) (QIAxcel 
system, Qiagen) has been improved. Furthermore, in order to overcome the 
comparatively low sensitivity of conventional PCR, a barcoding assay with 9 single 
nucleotide polymorphisms (SNPs) for genotyping of low-density P. falciparum 
infection by Taqman-probe-based end-point PCR was adapted from a published 
method. The alternative use of these two approaches will help to improve the accuracy 
of parasite genotyping, covering different types of samples, applications, and lab 
settings. 
The improved techniques were applied in two case scenarios: i) an epidemiological 
survey and ii) to assess parasite population structure in different compartments of the 
body.  
It was observed that in Lambaréné and surroundings, the multiplicity of infection (MOI) 
and prevalence of chloroquine-resistance-associated mutations remain high; 
particularly, in the most rural areas and despite a change in malaria control 
recommendations, including withdrawal of chloroquine from the market. Decreasing 
MOIs in central areas of Lambaréné may be the result of urbanization and its effect on 
transmission intensity and spread of drug resistance, which results in less diverse 
malaria parasite populations.  
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Within its human host, malaria parasite population structure in both severely anemic 
and control patients was shown to be similar between bone marrow and peripheral 
blood. If the differences observed in some patients is of pathophysiological importance 
remains to be further investigated.  
My thesis highlights the crucial role of adequate genotyping approaches in the 
development of malaria eradication tools, identifies a commonly available source of 
DNA for retrospective studies and suggests an improvement in the guidelines for 
sample collection and molecular analyses for studying malaria in endemic regions.  
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ZUSAMMENFASSUNG 
Zur Entwicklung und Verbesserung der Behandlung von Malaria ist es von großem 
Interesse die Populationsstruktur des Parasiten und die Wirt-Parasit Mechanismen zu 
verstehen. Diese Dissertation trägt dazu bei, bisherige Methoden zur Charakterisierung 
des Malariaparasiten zu verbessern und anzuwenden um aktuelle epidemiologischen 
Daten zu Plasmodium falciparum Populationen in Lambaréné, Gabun zu gewinnen.  
Die Ergebnisse dieser Arbeit zeigen, dass diagnostische Schnelltests (RDT) nicht nur 
zur unmittelbaren Diagnose, sondern auch als eine Quelle zur Isolierung von DNA 
geeignet sind. Diese kann für die Untersuchung der Verteilung unterschiedlicher 
Parasitenspezies und -stämme mittels molekularbiologischer Verfahren genutzt werden. 
Des Weiteren können die diagnostische Leistungsfähigkeit von RDTs und genetische 
Polymorphismen, wie z.B. Mutationen zu Resistenzen analysiert werden. Außerdem 
konnte die Methode der Genotypisierung des msp1 Gens anhand von 
Größenpolymorphismen verbessert werden. Dazu wurde eine konventionelle 
Polymerase Ketten Reaktion (PCR) durchgeführt und das PCR-Produkt anschließend 
mittels automatisierter Kapillarelektrophorese (QIAxcel System Qiagen) aufgetrennt. 
Um Detektionsprobleme durch die verhältnismäßig geringe Sensitivität der 
konventionellen PCR zu überwinden wurde ein Barcode-Assay mit 9 SNPs (single 
nucleotide polymorphism) zur Genotypisierung von Proben mit geringer P. falciparum-
Parasitämie auf Basis eines kommerziell erhältlichen Assays entwickelt und dessen 
Leistungsfähigkeit überprüft. Die so verbesserte Methodik erhöht die Genauigkeit der 
Genotypisierung, auch bei unterschiedlichen Arten von Probenmaterial, Anwendungen 
und Laborvoraussetzungen. Die im Rahmen der Dissertation etablierten Techniken 
wurden an zwei verschiedenen Kohorten angewendet: 1) Im Rahmen einer 
epidemiologischen Studie und 2) zur Untersuchung der Struktur von 
Parasitenpopulationen in verschiedenen Kompartimenten des Körpers.  
In Lambaréné und Umgebung ist die beobachtete Multiplizität der Infektion (MOI) und 
das Auftreten von mit Chloroquinresistenz assoziierten Mutationen immer noch hoch; 
insbesondere in den ländlichen Gegenden und trotz der aktuellen Empfehlungen zur 
Malariakontrolle, die unter anderem die Anwendung von Chloroquin verbieten. Die 
Reduktion der Anzahl von Mehrfachinfektionen in städtischen Gebieten Lambarénés, 
können das Ergebnis von Urbanisierung sein, die einen Effekte auf 
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Übertragungsintensität und Verbreitung von Resistenzbildung haben und mit der 
Abnahme der Diversität von Infektionen assoziiert ist.  
Die Untersuchung von zwei Kompartimenten (peripheres Blut und Knochenmark) des 
menschlichen Wirts zeigte, dass die Struktur der Parasitenpopulationen ähnlich ist und 
sich in anämischen nicht wesentlich von  Kontrollpatienten unterscheidet. Ob die 
Unterschiede, die in einzelnen Patienten beobachtet wurden, von pathophysiologischer 
Relevanz sind wird in weitergehenden Arbeiten untersucht werden.           
Meine Arbeit stellt die Wichtigkeit adäquater, gut etablierter und validierter Methoden 
zur Genotypisierung von Malariaparasiten dar und zeigt neue Quellen zur Gewinnung 
von DNA für retrospektive Studien auf. Dies ist entscheidend für die Entwicklung neuer 
Interventionen zur Kontrolle der Malaria. Außerdem lassen sich anhand der Arbeit 
Verbesserung zu den bisherigen Empfehlungen zur Probengewinnung und der 
molekularen Analyse zur Untersuchung von Malaria in endemischen Gebieten ableiten. 
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